You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 164 No. 22, Dec 13/27, 2004 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Editor's Correspondence
 •Online Features
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Neurology
 •Stroke
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Thrombophilia Screening and Ischemic Stroke

Since this article does not have an abstract, we have provided the first 147 words of the full text and any section headings.

In their review of patent foramen ovale in cryptogenic stroke, Wu et al1 include factor V Leiden, prothrombin 20210 mutation, proteins C and S deficiency, and antithrombin III deficiency among the thrombophilic abnormalities causing and predisposing to stroke and transient ischemic attack and recommend screening younger individuals presenting with stroke.

In contrast to the association between antiphospholipid antibodies and lupus anticoagulants and arterial thrombosis, these inherited thrombophilic abnormalities have been shown not to be significantly linked with stroke or transient ischemic attack.2 The high prevalence of these abnormalities makes the probability of a coincidental finding high. Although factor V Leiden and prothrombin 20210 mutation may play a small role in a subtype of stroke,3 their inclusion in the routine investigation of ischemic stroke is not recommended by current guidelines.4


AUTHOR INFORMATION
Correspondence: Dr Butler, Department of Haematology, Falkirk Royal Infirmary, Major’s Loan, Falkirk FK1 5QE, Scotland (andrew.butler@fvah.scot.nhs.uk).

Andrew Butler, MRCP, MRCPath; Roddy Neilson, MRCP, MRCPath

1. Wu LA, Malouf JF, Dearani JA, et al. Patent foramen ovale in cryptogenic stroke: current understanding and management options. Arch Intern Med. 2004;164:950-956. FREE FULL TEXT
2. Karttunen V, Hiltunen L, Rasi V, et al. Factor V Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale. Blood Coagul Fibrinolysis. 2003;14:261-268. FULL TEXT | WEB OF SCIENCE | PUBMED
3. Walker ID, Greaves M, Preston FE, et al. Investigation and management of heritable thrombophilia. Br J Haematol. 2001;114:512-528. FULL TEXT | WEB OF SCIENCE | PUBMED
4. Hankey GJ, Eikelboom JW, van Bockxmeer FM, et al. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke. 2001;32:1793-1799. FREE FULL TEXT

Arch Intern Med. 2004;164:2502.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Patent Foramen Ovale in Cryptogenic Stroke: Current Understanding and Management Options
Lambert A. Wu, Joseph F. Malouf, Joseph A. Dearani, Donald J. Hagler, Guy S. Reeder, George W. Petty, and Bijoy K. Khandheria
Arch Intern Med. 2004;164(9):950-956.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.